UBS Chair Colm Kelleher said that the Swiss government’s proposal to require the bank to hold substantially more capital is the “wrong remedy” to the failings […]
Zolgensma, a one-off treatment for infants born with a rare and often fatal genetic disease, came to the market five years ago at an eye-watering $2.1 […]